IDRSF - Idorsia GAAP EPS of -CHF1.25 revenue of CHF17M

• Idorsia press release ( OTCPK:IDRSF ): Q2 GAAP EPS of -CHF1.25.
• Revenue of CHF17M (+142.9% Y/Y).
• CFO comment: “Idorsia has reached another important milestone by recording its first product sales with the launches of PIVLAZ in Japan and QUVIVIQ in the US. Becoming a commercial stage company is a key milestone to achieve our objective of reaching sustainable profitability by 2025. The positive readout of aprocitentan in June is another key milestone as the royalty entitlement from Janssen will bring us another source of revenue by 2024. All these recent milestones make us confident that we will be able to raise cash with non-equity dilutive instruments in the second half of 2022. The next few months will give us more visibility on the uptake of QUVIVIQ in the US. Irrespective of the net sales numbers that will be achieved for the full year 2022, we are fully committed to delivering our current guidance with a non-GAAP operating loss around CHF 785 million and a US GAAP operating loss around CHF 840 million for the full year 2022.”

For further details see: